Details
Stereochemistry | MIXED |
Molecular Formula | C24H32N2O2 |
Molecular Weight | 380.5231 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=BSHWLCACYCVCJE-UHFFFAOYSA-N
InChI=1S/C24H32N2O2/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22/h4-13,20,23H,3,14-19H2,1-2H3
Molecular Formula | C24H32N2O2 |
Molecular Weight | 380.5231 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html
Curator's Comment: description was created based on several sources, including:
http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=421 | http://en.pharmacodia.com/web/drug/1_11802.html
Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing. It is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia The most commonly reported adverse reactions include loss of appetite, nausea/vomiting, stomach discomfort, diarrhea (including loose stool) and symptom of irritation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24849814 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia |
|||
Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia |
|||
Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia. |
|||
Palliative | Eftapan Approved UseIt is usually used to treat symptoms of cough and phlegm caused by respiratory diseases such as cold, upper respiratory infection, bronchitis, and pneumonia. |
Sample Use Guides
take 60-90mg of the active ingredient in 3 divided doses a day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24849814
Eprazinone displayed a rather weak inhibition of [125I]BH-SPbinding to NK1R, at a concentration of 25 uM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity or could even be a hint to a still unrevealed mode of action.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:41:05 GMT 2023
by
admin
on
Fri Dec 15 15:41:05 GMT 2023
|
Record UNII |
883YNL63WU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29767
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
||
|
WHO-VATC |
QR05CB04
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
||
|
NCI_THESAURUS |
C74536
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
||
|
WHO-ATC |
R05CB04
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
233-873-3
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
82716
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
100000084553
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
DTXSID1048336
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
SUB06583MIG
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
m4958
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
1035
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
Eprazinone
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
24272
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB08990
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
C65518
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
883YNL63WU
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1885437
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
C007608
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
2745
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
3245
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY | |||
|
10402-90-1
Created by
admin on Fri Dec 15 15:41:05 GMT 2023 , Edited by admin on Fri Dec 15 15:41:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |